Pep­tide biotech gets re­newed sup­port from Bris­tol My­ers, oth­ers to bankroll mul­ti­ple on­col­o­gy clin­i­cal pro­grams

The first batch of fi­nanc­ing last­ed about five years, but this time around, Sapi­ence Ther­a­peu­tics thinks its new fund­ing round will have run­way for less than two years, un­til the back half of 2023.

That’s be­cause the Har­ri­son, NY biotech has clin­i­cal pro­grams to fund. So, Nex­Point is join­ing ex­ist­ing back­ers Bris­tol My­ers Squibb, Es­hel­man Ven­tures and King­don Cap­i­tal in sup­ply­ing $41 mil­lion for a Se­ries B.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER